Key Highlights

  • Janux Therapeutics (NASDAQ:JANX) lost roughly a quarter of its value on November 9, 2026 after presenting initial Phase 1 data for JANX011 in healthy volunteers.
  • A single 3 mg dose produced peripheral B-cell depletion of more than 90% in three of five participants at that dose, with reductions lasting through Day 42.
  • All cytokine release syndrome events were Grade 1, with no serious adverse events or dose-limiting toxicities across 25 participants in five dose cohorts.
  • The company held USD 945.7 million in cash and short-term investments at September 30, 2026, and reported a third-quarter net loss of USD 21.6 million.

What JANX011 Is Designed to Do

JANX011 is the first clinical candidate from the Adaptive Immune Response Modulator platform of Janux Therapeutics (NASDAQ:JANX). It targets CD19, a marker on B cells, and is designed to deliver deep and durable B-cell depletion while limiting cytokine release, the inflammatory reaction that has constrained earlier T cell engagers. A distinguishing feature is that the molecule engages a narrow subset of T cells that express TRBV6, rather than the broad pool of CD3 positive T cells. The commercial goal is autoimmune disease, where resetting the B-cell compartment has produced striking results with cell therapies, and where a simple subcutaneous injection would be far easier to deliver. The Phase 1 study enrolled 25 healthy volunteers across five dose cohorts, from 30 micrograms to 3 mg, with a data cut-off of November 2, 2026.

Why the Data Disappointed the Market

The safety profile was clean, with only Grade 1 cytokine release events and no serious adverse events, but the depth of effect was less consistent than investors appear to have hoped. At the top 3 mg dose, depletion of more than 90% was seen in three of five participants, which leaves two participants below that threshold and a small sample on which to judge the curve. The stock had already fallen 11.7% to USD 16.06 on November 6, 2026 ahead of the release, showing that expectations were elevated and positioning was nervous. In a market that rewarded large, liquid growth names on November 9, an early-stage biotech with an ambiguous first readout became a source of funds. Healthy volunteer studies also say little about how patients with active autoimmune disease will respond, which adds to the uncertainty.

Balance Sheet and Next Milestones

Funding is the strongest part of the case. Janux Therapeutics (NASDAQ:JANX) ended the third quarter with USD 945.7 million in cash and short-term investments, against a quarterly net loss of USD 21.6 million, or USD 0.34 per share, and collaboration Revenue of USD 9.3 million. That gives a long runway to test higher doses or repeat dosing. The company plans to begin studies in immune thrombocytopenia in the first half of 2027 and in rheumatoid arthritis in the second half of 2027. Its prostate cancer candidate JANX007 remains in Phase 1b, with further data expected at a medical meeting in the first half of 2027. The main risks are that higher doses erode the clean safety profile, that depletion proves insufficient in patients, and that competition in B-cell resetting therapies intensifies before JANX011 reaches the clinic in disease.

Where Things Stand

Janux fell by roughly a quarter on November 9, 2026 because early JANX011 data, while clean on safety, showed deep B-cell depletion in only three of five participants at the top dose. A cash position of USD 945.7 million funds the next steps, which are dose optimisation and autoimmune patient studies starting in 2027. Patient data, rather than healthy volunteer results, will decide whether the platform earns back investor confidence.